Novel targeted protein degradation technologies as a therapeutic strategy for neurodegenerative diseases

Future Medicinal ChemistryVol. 15, No. 5 EditorialNovel targeted protein degradation technologies as a therapeutic strategy for neurodegenerative diseasesChangyu Ren, Jiao Liu, Shiyun Pu, Houfeng Zhou, Jinqi Li & Jifa ZhangChangyu RenDepartment of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, ChinaSearch for more papers by this author, Jiao LiuDepartment of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, ChinaSearch for more papers by this author, Shiyun PuDepartment of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, ChinaSearch for more papers by this author, Houfeng ZhouDepartment of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, ChinaSearch for more papers by this author, Jinqi Li*Author for correspondence: E-mail Address: lijinqi2002@126.comDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, 610072, ChinaSearch for more papers by this author & Jifa Zhang**Author for correspondence: E-mail Address: zjf298257@163.comDepartment of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, ChinaJoint Research Institution of Altitude Health, West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, ChinaSearch for more papers by this authorPublished Online:31 Mar 2023https://doi.org/10.4155/fmc-2023-0035AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: neurodegenerative diseasesnovel strategyproteolysis targeting chimerastargeted protein degradationReferences1. Kumar D, Md Ashraf G, Bilgrami AL, Imtaiyaz Hassan M. Emerging therapeutic developments in neurodegenerative diseases: a clinical investigation. Drug Discov. Today. 27(10), 103305 (2022).Crossref, Medline, CAS, Google Scholar2. Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat. Neurosci. 21(10), 1332–1340 (2018).Crossref, Medline, CAS, Google Scholar3. Tomoshige S, Ishikawa M. PROTACs and other chemical protein degradation technologies for the treatment of neurodegenerative disorders. Angew. Chem. Int. Ed. 60(7), 3346–3354 (2021).Crossref, Medline, CAS, Google Scholar4. Zalewska T, Pawelec P, Ziabska K, Ziemka-Nalecz M. Sexual dimorphism in neurodegenerative diseases and in brain ischemia. Biomolecules. 13(1), 26 (2022).Crossref, Medline, Google Scholar5. Balestrino R, Schapira AHV. Parkinson disease. Eur. J. Neurol. 27(1), 27–42 (2020).Crossref, Medline, CAS, Google Scholar6. Rana T, Behl T, Sehgal A et al. Exploring the role of autophagy dysfunction in neurodegenerative disorders. Mol. Neurobiol. 58(10), 4886–4905 (2021).Crossref, Medline, CAS, Google Scholar7. Araldi RP, D'Amelio F, Vigerelli H et al. Stem cell-derived exosomes as therapeutic approach for neurodegenerative disorders: from biology to biotechnology. Cells. 9(12), 2663 (2020).Crossref, Medline, CAS, Google Scholar8. Setten RL, Rossi JJ, Han S. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 18(6), 421–446 (2019).Crossref, Medline, CAS, Google Scholar9. Katti A, Diaz BJ, Caragine CM et al. CRISPR in cancer biology and therapy. Nat. Rev. Cancer. 22(5), 259–279 (2022).Crossref, Medline, CAS, Google Scholar10. Kargbo RB. PROTAC compounds targeting α-synuclein protein for treating neurogenerative disorders: Alzheimer's and Parkinson's diseases. ACS Med. Chem. Lett. 11(6), 1086–1087 (2020).Crossref, Medline, CAS, Google Scholar11. Chu T-T, Gao N, Li Q-Q et al. Specific knockdown of endogenous tau protein by peptide-directed ubiquitin-proteasome degradation. Cell Chem. Biol. 23(4), 453–461 (2016).Crossref, Medline, CAS, Google Scholar12. Fang Y, Wang J, Zhao M et al. Progress and challenges in targeted protein degradation for neurodegenerative disease therapy. J. Med. Chem. 65(17), 11454–11477 (2022).Crossref, Medline, CAS, Google Scholar13. Li H, Dong J, Cai M et al. Protein degradation technology: a strategic paradigm shift in drug discovery. J. Hematol. Oncol. 14(1), 138 (2021).Crossref, Medline, CAS, Google Scholar14. Naito M, Ohoka N, Shibata N. SNIPERs – hijacking IAP activity to induce protein degradation. Drug Discov. Today Technol. 31, 35–42 (2019).Crossref, Medline, Google Scholar15. Hirai K, Yamashita H, Tomoshige S et al. Conversion of a PROTAC mutant Huntingtin degrader into small-molecule hydrophobic tags focusing on drug-like properties. ACS Med. Chem. Lett. 13(3), 396–402 (2022).Crossref, Medline, CAS, Google Scholar16. Takahashi D, Arimoto H. Targeting selective autophagy by AUTAC degraders. Autophagy. 16(4), 765–766 (2020).Crossref, Medline, CAS, Google Scholar17. Ding Y, Fei Y, Lu B. Emerging new concepts of degrader technologies. Trends Pharmacol. Sci. 41(7), 464–474 (2020).Crossref, Medline, CAS, Google Scholar18. Zhang J, Huang Y, Liu W et al. Chaperone-mediated autophagy targeting chimeras (CMATAC) for the degradation of ERα in breast cancer. BIOCELL. 44(4), 591–595 (2020).Crossref, CAS, Google Scholar19. Dey SK, Jaffrey SR. RIBOTACs: small molecules target RNA for degradation. Cell Chem. Biol. 26(8), 1047–1049 (2019).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 15, No. 5 STAY CONNECTED Metrics Downloaded 55 times History Received 5 February 2023 Accepted 7 February 2023 Published online 31 March 2023 Published in print March 2023 Information© 2023 Newlands PressKeywordsneurodegenerative diseasesnovel strategyproteolysis targeting chimerastargeted protein degradationFinancial & competing interests disclosureThe authors thank the Natural Science Foundation of Sichuan (No. 2023NSFSC1695), Health Commission of Sichuan Province (No. 21PJ149) and Xinglin Foundation of Chengdu University of TCM (No. YYZX2021043). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download